An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non-muscle-invasive bladder cancer (NMIBC).

被引：0
|
作者：
DSouza, Neeta [1 ]
Gaffney, Christopher [1 ]
Hernandez, Christian [1 ]
Moran, Patricia [1 ]
Worth, Kara [1 ]
McCarter, Melissa [1 ]
de Jesus, Manuel R. [1 ]
Solit, David B. [1 ]
Sarungbam, Judy [1 ]
Al-Ahmadie, Hikmat A. [1 ]
Bochner, Bernard H. [1 ]
Iyer, Gopa [1 ]
Rosenberg, Jonathan E. [1 ]
Pietzak, Eugene J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4614
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION
    Neeta, D'Souza
    De Jesus, Escano Manuel
    Muneeb, Alam Syed
    Gao Sizhi
    Tang Xinran
    Alvin, Goh
    Bernard H, Bochner
    David, Solit
    Gopakumar, Iyer
    Hikmat, Al-Ahmadie
    Eugene, Pietzak
    Priya, Dave
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S55 - S55
  • [2] Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediaterisk non-muscle-invasive bladder cancer (IR-NMIBC) with FGFR3/2 alterations (alt) in THOR-2: Cohort 3 interim analysis.
    Daneshmand, Siamak
    Zaucha, Renata
    Gartrell, Benjamin Adam
    Lotan, Yair
    Hussain, Syed A.
    Lee, Eugene K.
    Procopio, Giuseppe
    Galanternik, Fernando
    Naini, Vahid
    Carcione, Jenna
    Triantos, Spyros
    Baig, Mahadi
    Maranchie, Jodi K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Phase III prevention trial of Fenretinide in patients with resected non-muscle-invasive bladder cancer
    Sabichi, Anita L.
    Lerner, Seth P.
    Atkinson, E. Neely
    Grossman, H. Barton
    Caraway, Nancy P.
    Dinney, Colin P.
    Penson, David F.
    Matin, Surena
    Kamat, Ashish
    Pisters, Louis L.
    Lin, Daniel W.
    Katz, Ruth L.
    Brenner, Dean E.
    Hemstreet, George P., III
    Wargo, Mary
    Bleyer, Archie
    Sanders, William H.
    Clifford, John L.
    Parnes, Howard L.
    Lippman, Scott M.
    CLINICAL CANCER RESEARCH, 2008, 14 (01) : 224 - 229
  • [4] Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-inhuman study.
    Vilaseca, Antoni
    Guerrero, Felix
    Zainfeld, Daniel
    Shore, Neal D.
    Rodriguez Faba, Oscar
    Meijer, Richard P.
    Alfred Witjes, Alfred
    Jackson McRee, Autumn
    Kalota, Anna
    Stone, Nicole L.
    David Lauring, Josh
    Zhu, Wei
    Beeharry, Neil
    O'Dondi, Lang A.
    Jayram, Gautam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC)
    Roperch, Jean-Pierre
    Hennion, Claude
    BMC MEDICAL GENETICS, 2020, 21 (01)
  • [6] FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER WITH SELECT FGFR ALTERATIONS
    Vilaseca, Antoni
    Jayram, Gautam
    Raventos, Carles
    Shore, Neal D.
    Zainfeld, Daniel
    Kang, Taek Won
    Ku, Ja Hyeon
    Meeks, Joshua
    Rodriguez Faba, Oscar
    Roghmann, Florian
    Daneshmand, Siamak
    Beeharry, Neil
    Cost, Carrye R.
    Kalota, Anna
    Lauring, Josh
    Peterson, Michelle R.
    Quiroz, Michelle
    Stone, Nicole L.
    Zhu, Wei
    Gurrero Ramos, Felix
    JOURNAL OF UROLOGY, 2024, 211 (05): : E987 - E988
  • [7] Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study
    Kawahara, Takashi
    Kandori, Shuya
    Kojima, Takahiro
    Mathis, Bryan J.
    Shiga, Masanobu
    Nishiyama, Hiroyuki
    BMC RESEARCH NOTES, 2025, 18 (01)
  • [8] First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Rodriguez Faba, O.
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C. R.
    Kalota, A.
    Lauring, J.
    Peterson, M. R.
    Quiroz, M. Q.
    Stone, N. L.
    Zhu, W.
    Gurrero-Ramos, F.
    EUROPEAN UROLOGY, 2024, 85 : S1506 - S1507
  • [9] A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
    Packiam, Vignesh T.
    Campanile, Alexa N.
    Barocas, Daniel A.
    Chamie, Karim
    Davis, Ronald L., III
    Kader, A. Karim
    Lamm, Donald L.
    Yeung, Alex W.
    Steinberg, Gary D.
    JOURNAL OF UROLOGY, 2016, 195 (04): : E142 - E142
  • [10] Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).
    Halachmi, Sarel
    Leibovitch, Ilan
    Zisman, Amnon
    Stein, Avi
    Benjamin, Shalva
    Sidi, Ami
    Knickerbocker, Ron
    Limor, Michal
    Moore, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345